Cargando…

Stem cell transplantation for the treatment of end-stage liver disease

The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dong-Bo, Chen, En-Qiang, Tang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323519/
https://www.ncbi.nlm.nih.gov/pubmed/30631395
http://dx.doi.org/10.4254/wjh.v10.i12.907
_version_ 1783385782541615104
author Wu, Dong-Bo
Chen, En-Qiang
Tang, Hong
author_facet Wu, Dong-Bo
Chen, En-Qiang
Tang, Hong
author_sort Wu, Dong-Bo
collection PubMed
description The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, stem cell-based therapies are effective in many diseases, and provide novel insights into the treatment of end-stage liver disease. Several clinical trials have indicated the efficacy profiles of stem cell transplantation in patients with end-stage liver disease, including liver cirrhosis, liver failure, and liver tumors. Animal models of acute liver failure have also provided important insights into the safety, mechanisms, and efficacy of stem cell therapies. Nevertheless, excitement due to this promising field must be tempered with careful and calculated research. In particular, studies on the quality, safety, and efficacy of stem cell transplantation are needed to ensure that qualified products are tested in well-designed clinical trials and approved by governments. Therefore, further investigations are required to effectively balance the safety with the innovation of stem cell transplantation research toward the effective treatment of end-stage liver disease.
format Online
Article
Text
id pubmed-6323519
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-63235192019-01-10 Stem cell transplantation for the treatment of end-stage liver disease Wu, Dong-Bo Chen, En-Qiang Tang, Hong World J Hepatol Editorial The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, stem cell-based therapies are effective in many diseases, and provide novel insights into the treatment of end-stage liver disease. Several clinical trials have indicated the efficacy profiles of stem cell transplantation in patients with end-stage liver disease, including liver cirrhosis, liver failure, and liver tumors. Animal models of acute liver failure have also provided important insights into the safety, mechanisms, and efficacy of stem cell therapies. Nevertheless, excitement due to this promising field must be tempered with careful and calculated research. In particular, studies on the quality, safety, and efficacy of stem cell transplantation are needed to ensure that qualified products are tested in well-designed clinical trials and approved by governments. Therefore, further investigations are required to effectively balance the safety with the innovation of stem cell transplantation research toward the effective treatment of end-stage liver disease. Baishideng Publishing Group Inc 2018-12-27 2018-12-27 /pmc/articles/PMC6323519/ /pubmed/30631395 http://dx.doi.org/10.4254/wjh.v10.i12.907 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Editorial
Wu, Dong-Bo
Chen, En-Qiang
Tang, Hong
Stem cell transplantation for the treatment of end-stage liver disease
title Stem cell transplantation for the treatment of end-stage liver disease
title_full Stem cell transplantation for the treatment of end-stage liver disease
title_fullStr Stem cell transplantation for the treatment of end-stage liver disease
title_full_unstemmed Stem cell transplantation for the treatment of end-stage liver disease
title_short Stem cell transplantation for the treatment of end-stage liver disease
title_sort stem cell transplantation for the treatment of end-stage liver disease
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323519/
https://www.ncbi.nlm.nih.gov/pubmed/30631395
http://dx.doi.org/10.4254/wjh.v10.i12.907
work_keys_str_mv AT wudongbo stemcelltransplantationforthetreatmentofendstageliverdisease
AT chenenqiang stemcelltransplantationforthetreatmentofendstageliverdisease
AT tanghong stemcelltransplantationforthetreatmentofendstageliverdisease